00:45 , Dec 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest inhibiting USP13 could help treat ovarian cancer. In patient samples, levels of USP13 were higher in tumors than in adjacent normal ovarian tissue, and tumor...
00:53 , Mar 17, 2015 |  BC Extra  |  Company News

Management tracks

Oral therapies developer Chiasma Inc. (Jerusalem, Israel) named Mark Leuchtenberger president and CEO. Leuchtenberger was president and CEO of Acusphere Inc. (Pink:ACUS). Leuchtenberger succeeds Roni Mamluk, whom Chiasma named chief development officer. mRNA technology company...
07:00 , May 12, 2014 |  BC Week In Review  |  Company News

Xenetic board of directors update

Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass.   Business: Drug delivery   Appointed: Mark Leuchtenberger, president and CEO of Acusphere Inc., as non-executive chairman; he succeeds Brian Richards, who remains chair of Xenetic's scientific advisory board   ...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Acusphere management update

Acusphere Inc. (Pink:ACUS), Lexington, Mass.   Business: Diagnostic, Drug delivery   Transitioned: William Ramage to chief development officer from executive consultant   ...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Acusphere management update

Acusphere Inc. (Pink:ACUSD), Lexington, Mass.   Business: Diagnostic, Drug delivery   Hired: Mark Leuchtenberger as president, CEO and a director, formerly president, CEO and a director of Rib-X Pharmaceuticals Inc.; he succeeds Co-Founder Serri Oberg, who...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Imagify perflubutane regulatory update

Acusphere said it completed an MAA dossier for Imagify perflubutane polymer microspheres to detect coronary artery disease and is in the process of filing it with EMA. In 2009, Acusphere received a complete response letter...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Financial News

Acusphere completes convertible debt financing

Acusphere Inc. (Pink:ACUSD), Lexington, Mass.   Business: Diagnostic, Drug delivery   Date completed: 7/9/12   Type: Convertible debt financing   Raised: $3.5 million   Shares outstanding prior: 5.1 million   Investor: Burrill   Note: The company drew down $3.5 million of an...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Financial News

Acusphere financial update

Acusphere shareholders approved a 1-for-10 reverse stock split. Following the split, the company will have 5.1 million shares outstanding. Acusphere Inc. (Pink:ACUS), Lexington, Mass.   Business: Diagnostic, Drug delivery   Date announced: 1/20/12   ...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

3Q Financial Markets Preview: Flavored with Phase III

The upcoming clinical and regulatory calendar isn't as densely packed as it was in the first half. But biotech investors are looking especially to Phase III data across all market cap segments through year end. Among...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

Imagify perflubutane: SPA received

Acusphere received an SPA from FDA for a planned placebo-controlled Phase III trial to evaluate Imagify perflubutane in about 900 patients. The company did not disclose a timeline to begin the trial. In 2009, Acusphere...